Related coverage linked through entity extraction aliases.
Apr 09, 2026
Trump proposed significant cuts to major US science agencies for 2027, including a 13% reduction for the NIH and a nearly 55% cut for the NSF. The administration also let lapse its Supreme Court deadline in a separate fight to cap NIH research overhead payments at 15%.
Mar 20, 2026
The FDA announced major policy changes including requiring only one study for drug approvals instead of two, and offering performance bonuses to reviewers who complete work ahead of schedule while maintaining thoroughness.
Mar 20, 2026
The U.S. Department of Health and Human Services formally scrapped its 2025 340B Rebate Model Pilot Program following federal court rulings and issued a new Request for Information on February 13, 2026, seeking stakeholder input on the future of 340B drug pricing.
Mar 14, 2026
Sen. Josh Hawley and Rep. Diana Harshbarger introduced legislation to withdraw FDA approval of mifepristone nationwide, making distribution a federal violation and allowing patients to sue manufacturers.
Feb 18, 2026
European regulators approved a 7.2mg "megadose" of Novo Nordisk's Wegovy involving three weekly injections. The Danish drugmaker filed suit against Hims & Hers after the telehealth company briefly launched a compounded oral semaglutide product.
Feb 10, 2026
Hims and Hers Health pulled its $49 compounded version of Novo Nordisk's Wegovy weight-loss pill after the FDA referred the company to the Department of Justice for potential legal violations.
